Synthesis and Biological Activity of Imidazo[4,5-c]quinoline Derivatives as PI3K/mTOR Inhibitors

被引：5
|
作者：
Li Yanjie [1 ,2 ]
Zhang Xingmin [3 ]
Niu Shengxiu [1 ]
Zhao Yanping [1 ]
Yang Lijuan [1 ]
Shao Xiaowei [1 ]
Wang Ensi [1 ]
机构：
[1] Jilin Univ, Coll Pharm, Changchun 130021, Jilin, Peoples R China
[2] Changchun Univ Tradit Chinese Med, Coll Pharm, Changchun 130117, Jilin, Peoples R China
[3] Beijing Foreland Pharma Biol Technol Co Ltd, Beijing 101111, Peoples R China
来源：
CHEMICAL RESEARCH IN CHINESE UNIVERSITIES | 2017年 / 33卷 / 06期
关键词：
Imninzo[4,5-c]quinoline; Suzuki reaction; Dual PI3K/mTOR inhibitor; NVP-BEZ235; TARGET; MUTATIONS; RAPAMYCIN; GROWTH; CANCER;
D O I：
10.1007/s40242-017-7074-1
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
A series of imidazo[4,5-c]quinoline derivatives(12a-12m) was synthesized with 2-amino-5-bromobenzoic acid and 4-nitrophenylacetonitrile as starting materials, 6-bromo-4-chloro-3-nitroquinoline as intermediate and Suzuki reaction and closure of the imidazolinone ring with triphosgene as key steps. The structures of the key intermediate and target compounds were confirmed by means of H-1-INMR, C-13 NMR and HRMS. These compounds show an interesting kinase profile as dual PI3K/mTOR tool compounds.
引用
收藏
页码：895 / 902
页数：8
相关论文
共 50 条
  • [21] Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity
    Liao, Weike
    Wang, Zhongyuan
    Han, Yufei
    Qi, Yinliang
    Liu, Jiaan
    Xie, Juan
    Tian, Ye
    Lei, Qiancheng
    Chen, Rui
    Sun, Ming
    Tang, Lei
    Gong, Guowei
    Zhao, Yanfang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 197
  • [22] Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma
    Zhang, Lishun
    Yang, Zichao
    Sang, Huiting
    Jiang, Ying
    Zhou, Mingfeng
    Huang, Chuan
    Huang, Chunhui
    Wu, Xiaoyun
    Zhang, Tingting
    Zhang, Xingmei
    Wan, Shanhe
    Zhang, Jiajie
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2021, 36 (01) : 1541 - 1552
  • [23] Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors
    Wang, Zi-Xiao
    Wang, Shuai
    Qiao, Xue-Peng
    Li, Wen-Bo
    Shi, Jian-Tao
    Wang, Yi-Ru
    Chen, Shi-Wu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 74
  • [24] Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure-Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives
    Nishimura, Nobuko
    Siegmund, Aaron
    Liu, Longbin
    Yang, Kevin
    Bryan, Marian C.
    Andrews, Kristin L.
    Bo, Yunxin
    Booker, Shon K.
    Caenepeel, Sean
    Freeman, Daniel
    Liao, Hongyu
    McCarter, John
    Mullady, Erin L.
    San Miguel, Tisha
    Subramanian, Raju
    Tamayo, Nuria
    Wang, Ling
    Whittington, Douglas A.
    Zalameda, Leeanne
    Zhang, Nancy
    Hughes, Paul E.
    Norman, Mark H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (13) : 4735 - 4751
  • [25] PI3K and mTOR inhibitors - a new generation of targeted anticancer agents
    Brachmann, Saskia
    Fritsch, Christine
    Maira, Saveur-Michel
    Garcia-Echeverria, Carlos
    CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (02) : 194 - 198
  • [26] Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    Serova, Maria
    de Gramont, Armand
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Riveiro, Maria Eugenia
    Slimane, Khemaies
    Faivre, Sandrine
    Raymond, Eric
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1297 - 1307
  • [27] Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity
    Tian, Chengze
    Yang, Chengbin
    Wu, Tianze
    Lu, Mingzhu
    Chen, Yi
    Yang, Yongtai
    Liu, Xiaofeng
    Ling, Yun
    Deng, Mingli
    Jia, Yu
    Zhou, Yaming
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 48
  • [28] Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors
    Fan, Yan-Hua
    Li, Wei
    Liu, Dan -Dan
    Bai, Meng-Xuan
    Song, Hong-Rui
    Xu, Yong -Nan
    Lee, SangKook
    Zhou, Zhi-Peng
    Wang, Jian
    Ding, Huai-Wei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 139 : 95 - 106
  • [29] Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
    Sabbah, D. A.
    Brattain, M. G.
    Zhong, H.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (36) : 5528 - 5544
  • [30] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
12345